© 2007 European Society for Medical Oncology
hematologic malignancies |
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-
2b in patients with multiple myeloma maintained on a steady dose of interferon-2b
Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Surrey SM2 5PT and Clinical Trials and Statistics Unit, Institute of Cancer Research, UK
* Correspondence to: Prof. R. Powles, Parkside Cancer Centre, 49 Parkside, Wimbledon SW19 5NB, UK. Tel: +44-20-8944-7979; Fax: +44-20-8605-9103; E-mail: myeloma{at}clara.co.uk
Purpose: To compare the effects of pegylated interferon-
2b (P-IFN) and interferon-2b (IFN) on quality of life (QoL) and toxicity in patients with multiple myeloma maintained on a steady dose of IFN.
Patients and methods: Consenting, eligible myeloma patients on IFN maintenance therapy for at least 6 weeks were randomly (1:1) allocated to receive P-IFN for 3 months followed by IFN for 3 months, or to continue with IFN for 3 months followed by P-IFN for 3 months (cross-over design). Patients were assessed for toxicity and QoL. Dose of P-IFN was equivalent to IFN.
Results: The study enrolled 60 patients. At enrolment, 35 patients were in complete remission, 20 in partial remission and 5 were minimal responders. P-IFN was associated with significantly better global QoL score (mean difference 8.4; P = 0.0002). There was a significant improvement in functional scales—physical (P = 0.03), emotional (P = 0.04), social (P = 0.0008) with P-IFN. Fatigue (P = 0.0003), pain (P = 0.02) and appetite loss (P = 0.003) symptom scales were less in patients while on P-IFN. There were no statistically significant differences between treatment arms in QoL as measured by QLQ-MY24.
Conclusion: These data suggest that patients on P-IFN have a better QoL. Dose escalation studies are warranted to investigate potential impact on survival.
Key words: maintenance therapy, myeloma, pegylated interferon, quality of life
Received for publication December 22, 2006. Revision received March 30, 2007. Accepted for publication April 4, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Vangsted, T. W. Klausen, P. Gimsing, N. F. Andersen, N. Abildgaard, H. Gregersen, and U. Vogel A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support Haematologica, September 1, 2009; 94(9): 1274 - 1281. [Abstract] [Full Text] [PDF]
|
|